See more : Unitech Limited (UNITECH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of XORTX Therapeutics Inc. (XRTX.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XORTX Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Parkway Life Real Estate Investment Trust (C2PU.SI) Income Statement Analysis – Financial Results
- Gesco AG (0Q4C.L) Income Statement Analysis – Financial Results
- Eloxx Pharmaceuticals, Inc. (ELOX) Income Statement Analysis – Financial Results
- Renishaw plc (RSW.L) Income Statement Analysis – Financial Results
- Glenveagh Properties PLC (GLV.L) Income Statement Analysis – Financial Results
XORTX Therapeutics Inc. (XRTX.V)
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 141.96K | 75.27K | 17.88K | 20.44K | 19.90K | 19.32K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -141.96K | -75.27K | -17.88K | -20.44K | -19.90K | -19.32K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.41M | 6.49M | 669.11K | 277.46K | 39.90K | 342.25K | 66.37K | 0.00 | 0.00 |
| General & Administrative | 1.07M | 2.29M | 1.58M | 1.10M | 506.17K | 795.65K | 380.92K | 389.32K | 36.92K |
| Selling & Marketing | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39M | 2.29M | 1.58M | 1.10M | 506.17K | 795.65K | 380.92K | 389.32K | 36.92K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.64M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.81M | 9.86M | 2.86M | 1.30M | 565.97K | 1.16M | 464.07K | 405.34K | 36.92K |
| Cost & Expenses | 4.81M | 9.86M | 2.86M | 1.30M | 565.97K | 1.16M | 464.07K | 405.34K | 36.92K |
| Interest Income | 257.65K | 101.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 4.39K | 13.51K | 37.21K | 22.30K | 15.46K | 8.63K | 0.00 |
| Depreciation & Amortization | 188.54K | 75.27K | 17.88K | 20.44K | 19.90K | 19.32K | 16.78K | 16.02K | 0.00 |
| EBITDA | -6.47M | -9.41M | -1.63M | -1.25M | -572.47K | -1.07M | -427.11K | -389.32K | -36.92K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.81M | -10.69M | -4.14M | -1.30M | -565.97K | -1.16M | -469.44K | -405.34K | -36.92K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.95M | 2.95M | 1.25M | -202.36K | -63.61K | -2.71M | -47.09K | -25.52K | 0.00 |
| Income Before Tax | -2.86M | -6.99M | -1.30M | -1.28M | -629.58K | -3.78M | -474.20K | -414.83K | -36.92K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 4.39K | 13.51K | 37.21K | 22.30K | 10.09K | 8.63K | 0.00 |
| Net Income | -2.86M | -6.99M | -1.30M | -1.28M | -629.58K | -3.78M | -474.20K | -414.83K | -36.92K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -4.72 | -1.19 | -1.73 | -1.06 | -6.45 | -2.24 | -2.05 | -0.49 |
| EPS Diluted | -1.44 | -4.72 | -1.19 | -1.73 | -1.06 | -6.45 | -2.24 | -2.05 | -0.49 |
| Weighted Avg Shares Out | 1.98M | 1.48M | 1.09M | 740.45K | 595.49K | 584.99K | 211.45K | 202.74K | 75.57K |
| Weighted Avg Shares Out (Dil) | 1.98M | 1.48M | 1.09M | 740.45K | 595.49K | 584.99K | 211.45K | 202.74K | 75.57K |
Source: https://incomestatements.info
Category: Stock Reports